Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

Molecular Partners announced preclinical data for MP0632, a logic-gated Switch-DARPin T cell engager targeting MSLN and EpCAM co-expressing tumors. The data demonstrates potent tumor cell killing comparable to clinical-stage benchmarks with improved safety profiles and no detectable impact on healthy tissues. The company plans to advance MP0632 into IND-enabling studies for solid tumors including ovarian, endometrial, lung, and pancreatic cancers.